An upcoming second-line SCLC phase 3 will include Imdelltra as a control option.

The company plans a pivotal pancreatic cancer trial after seeing two responses in eight patients.

The G12C-selective elironrasib produces a 42% ORR in post-Lumakras/Krazati patients.

Amgen and Zai Lab’s FGFR2b antibody shows no benefit at the two-year mark.

A Chinese phase 3 of the biparatopic DLL3 T-cell engager alveltamig will start soon.

The Kandlelit-007 trial will assess MK-1084 plus SC Keytruda across PD-L1 expression levels.

Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.

Early data with IDE849 look better those with Zai’s zocilurtatug pelitecan.

Ocular toxicities could be the reason.